News | May 28, 2025
Granules India posts Q4 FY25 PAT at Rs. 152 Cr
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Delivers robust earnings performance, successfully navigating a dynamic environment
Overall investment in the US facility is estimated around US$50 million
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Granules India has reported consolidated financial results for the period ended December 31, 2021
The investment will increase SpeeDx internal capacity to scale up manufacturing
The company has tied up with OrbiMed as a financial partner for global reach
Subscribe To Our Newsletter & Stay Updated
